Investor Presentation Full Year 2021
12
Investor presentation Full year 2021
Total RybelsusⓇ TRx volume is steadily growing in the US
RybelsusⓇ and SGLT-21 uptake in the US² since respective launches
NBRX count
......
(000s)
RybelsusⓇ NBRX
RybelsusⓇ TRX
10
8
6
4
2
2019
SGLT-2i NBRX
SGLT-2i TRX
TRx count
(000s)
75
66
60
Time since launch (weeks)
2020
2021
91
97
103
109
45
46
30
115
2022
0
15
For the full year 2021, RybelsusⓇ sales approaches DKK 5 billion
RybelsusⓇ has now been launched in 29 countries
In the US:
.
•
Successful RybelsusⓇ launch despite COVID-19 impacting the first
year of launch
RybelsusⓇ TRX steadily increasing, reaching +45,000 Rx per week
Outside of the US:
•
In Japan, RybelsusⓇ has reached a 2.6% MOAD value market share
following lift of the 14-day prescription limitation in December 2021
1SGLT-2i is an average of empagliflozin and canagliflozin script count. 2Rybelsus® is based on Oct 2019 focus launch. Each data points represents a rolling four-week average.
Note: NBRx: New-to-brand prescriptions; RHS: Right hand side axis; HCP: Healthcare Professional; TRX: Total prescription data; MOAD: Modern oral anti-diabetics and includes SGLT-2is, DPP-IVis and Oral GLP-1.
Source: IQVIA Xponent, Weekly (ending 7 January 2022)
Novo NordiskⓇView entire presentation